Key clinical point: There’s no need for blood draws and laboratory monitoring in adolescent atopic dermatitis patients on dupilumab.

Major finding: Hematologic and serum chemistry findings were unremarkable in adolescents during 52 weeks on dupilumab for atopic dermatitis.

Study details: The LIBERTY AD PED-OLE study is an ongoing phase 3, open-label extension study of patients on dupilumab aged 6 months through 17 years.

Disclosures: The study is sponsored by Sanofi and Regeneron. The presenter reported receiving research funding from and serving as a consultant to those pharmaceutical companies and numerous others.